Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kozo Nishiyama is active.

Publication


Featured researches published by Kozo Nishiyama.


Clinical Endocrinology | 1997

High Incidence of Positive Autoantibodies against Thyroid Peroxidase and Thyroglobulin in Patients with Sarcoidosis

Hirotoshi Nakamura; Rieko Genma; Tomoko Mikami; Akira Kitahara; Hiroko Natsume; Shinichiro Andoh; Shinsuke Nagasawa; Kozo Nishiyama; Kingo Chida; Atsuhiko Sato; Teruya Yoshimi

OBJECTIVE Although abnormalities of the humoral immune system, such as increased immunoglobulin production, are known in sarcoidosis, the relationship between sarcoidosis and autoimmune disorders is uncertain. We studied the incidence of thyroid autoantibodies and the prevalence of Hashimoto’s thyroiditis in patients with sarcoidosis.


Genomics | 1992

A single serine:pyruvate aminotransferase gene on rat chromosome 9q34-q36

Masayuki Mori; Toshiaki Oda; Kozo Nishiyama; Tadao Serikawa; Junzo Yamada; Arata Ichiyama

It was found in our previous study (Oda et al., 1990. J. Biol. Chem. 265: 7513-7519) that in the rat two mRNAs encoding mitochondrial and peroxisomal serine:pyruvate aminotransferase (SPT/AGT) are formed from a single SPT/AGT gene through alternative transcription initiation in exon 1. In an attempt to analyze the mechanisms underlying this unique phenomenon, we have isolated genomic clones harboring the entire rat SPT/AGT gene. In the present study, the location of the rat SPT/AGT gene was determined to be in the q34-q36 region of chromosome 9 by fluorescence in situ hybridization. Southern blot analysis of rat genomic DNA revealed an allelic BamHI restriction fragment length polymorphism among three different inbred rat strains. These results indicated that a single copy SPT/AGT gene is located on chromosome 9q34-q36 in the rat genome. This locus has been assigned the gene symbol Spat.


Clinical Endocrinology | 1996

Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism

Hirotoshi Nakamura; Tomoko Mori; Rieko Genma; Yoshikazu Suzuki; Hiroko Natsume; Shinichiro Andoh; Ryo Kitahara; Shinsuke Nagasawa; Kozo Nishiyama; Teruya Yoshimi

OBJECTIVE We measured pyridinium cross‐links, markers of bone resorption, by an enzyme‐linked immunosorbent assay (ELISA) in hypothyroid patients to see whether bone resorption was reduced in hypothyroidism and whether it increased with T4 treatment.


Metabolism-clinical and Experimental | 1998

Alterations in the enzyme activity and protein contents of protein disulfide isomerase in rat tissues during fasting and refeeding

Tomoko Mikami; Rieko Genma; Kozo Nishiyama; Shinichiro Ando; Akira Kitahara; Hiroko Natsume; Teruya Yoshimi; Ryuya Horiuchi; Hirotoshi Nakamura

Protein disulfide isomerase (PDI) is an enzyme that participates in the formation of disulfide bonds. It is also known to be the subunits of some enzymes and the membrane-associated thyroid hormone-binding protein. In this study, we measured the quantitative distribution of PDI protein in rat tissues and examined the relationship between protein level and enzyme activity in PDI during fasting and refeeding. Western blotting with specific anti-PDI antiserum detected the PDI protein band of 55 kd. Among several tissues, liver contained the largest amount of PDI protein, followed by kidney and fat, in which one-third to one-fourth of the hepatic PDI protein existed. The PDI protein band was also detected in heart and muscle. Fasting for 3 days decreased PDI protein levels in rat liver by 40%; control levels were recovered after 3 days of refeeding. The same change was observed in kidney. PDI activity, measured by the scrambled ribonuclease method, did not show the parallel alteration to PDI protein level in liver and kidney. Isomerase activity decreased to 50% of control values during fasting, but did not recover by refeeding. Thyroidal status did not affect either PDI protein level or isomerase activity. These findings show that fasting and refeeding affect PDI protein and enzyme activity, and that PDI protein level does not always reflect PDI activity.


Molecular and Cellular Endocrinology | 1998

Difference in dominant negative activities between mutant thyroid hormone receptors α1 and β1 with an identical truncation in the extreme carboxyl-terminal tau4 domain

Kozo Nishiyama; Shinichiro Andoh; Akira Kitahara; Hiroko Natsume; Tomoko Mikami; Rieko Genma; Hirotoshi Nakamura

Although different expression patterns of thyroid hormone receptor (TR) alpha1 and beta1 have been reported, no essential distinction has been established in their functions. Unlike the TR beta gene, a mutation in the TR alpha1 gene has never been found in patients with resistance to thyroid hormone (RTH). Previously we found a mutant TR beta with an 11-carboxyl (C)-terminal amino acid truncation (betaF451X) in a girl with severe RTH. BetaF451X is a natural mutant with disruption of the transactivation domain, tau4, and it had very strong dominant negative activities. Based on the fact that the 46 amino acid sequence in the extreme C-terminal region is identical in TR alpha1 and TR beta, except for a C-terminal three amino acid extension of TR alpha1, we constructed a mutant TR alpha1 (alphaF397X) with the identical C-terminal truncation to betaF451X, to study functional differences between TR alpha1 and beta1. Both betaF451X and alphaF397X had negligible T3 binding and transcriptional activities even with 1 microM T3. The dominant negative activities of the mutant TRs were remarkable and T3 response element (TRE)-dependent. Co-expression of betaF451X decreased the CAT activity of either wild-type TR alpha1 or beta1 at 100 nM T3 by approximately 90% on the TRE-pal2 and 70% on DR4. AlphaF397X inhibited the transcriptional activities of both wild-type TR alpha1 and beta1 by approximately 50% on TRE-pal2 and by 60% on DR4. The dominant negative potency of betaF451X was significantly stronger than that of alphaF397X on the TRE-pal2, -DR4 and chicken lysozyme silencer F2, but similar on TRE-myosin heavy chain alpha and malic enzyme. No partiality for the TR subtypes was found in the dominant negative effects of betaF451X and alphaF397X. Co-expression with RXR enhanced the dominant negative effects of alphaF397X, but not of betaF451X. The results indicate that there are different dominant negative properties between alphaF397X and betaF451X, which are TRE-dependent, despite their identical C-terminal truncation. Deletion in the tau4 domain might affect the receptor structures of TR alpha1 and beta1 differently.


Biochemical and Biophysical Research Communications | 2003

β-Catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone

Hiroko Natsume; Shigekazu Sasaki; Masatoshi Kitagawa; Yumiko Kashiwabara; Akio Matsushita; Keiko Nakano; Kozo Nishiyama; Koji Nagayama; Hiroko Misawa; Hiroko Masuda; Hirotoshi Nakamura


Biochemical Journal | 2004

Thyroid-hormone-dependent negative regulation of thyrotropin beta gene by thyroid hormone receptors: study with a new experimental system using CV1 cells.

Keiko Nakano; Akio Matsushita; Shigekazu Sasaki; Hiroko Misawa; Kozo Nishiyama; Yumiko Kashiwabara; Hirotoshi Nakamura


Biochemical and Biophysical Research Communications | 1991

Primary hyperoxaluria type I due to a point mutation of T to C in the coding region of the serine:pyruvate aminotransferase gene

Kozo Nishiyama; Tsuneyoshi Funai; Ritsuko Katafuchi; Fumitada Hattori; Kaoru Onoyama; Arata Ichiyama


FEBS Journal | 1990

Cloning and nucleotide sequence of cDNA encoding human liver serine-pyruvate aminotransferase

Kozo Nishiyama; Gabriel Berstein; Toshiaki Oda; Arata Ichiyama


Journal of Endocrinology | 2000

Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT

Akio Matsushita; Hiroko Misawa; Shinichiro Andoh; Hiroko Natsume; Kozo Nishiyama; Shigekazu Sasaki; Hirotoshi Nakamura

Collaboration


Dive into the Kozo Nishiyama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge